Novartis' number of full-time employees by division 2013-2014
This statistic shows the number of people employed full-time by the Swiss-based pharmaceutical company Novartis in 2013 and 2014, sorted by division. In 2013, Novartis reported 9,213 employees in its Consumer Health division.
Novartis AG company facts
Novartis AG was formed in 1996, through a merger between Ciba-Geigy and Sandoz and their pharmaceutical and agrochemical divisions. It is a pharmaceutical company that is headquartered in Basel, Switzerland, with over 10,000 people working at the Basel Campus from around the world. Novartis reported varying number of employees working in different divisions within the company. There was an decrease from over 65 thousand employees in 2013 to some 59 thousand employees in 2014 working in the pharmaceutical division. Other divisions such as vaccines and diagnostics as well as consumer health also saw an decrease in the number of people employed in this period.
Novartis AG is one of the top pharmaceutical companies in the world with 17.2 billion U.S. dollars in European prescription drug revenues in 2013. In the same year, Novartis AG spent 9.6 billion U.S. dollars on research and development, a large increase from 2004 spending at only 4 billion U.S. dollars. Based on revenue, some of Novartis’ leading drug products include Gleevec/Glivec and Lucentis. Imatinib is marketed as Gleevec in Canada, South Africa, and the United States and as Glivec in Europe, Australia, and Latin America.
Novartis AG company facts
Novartis AG was formed in 1996, through a merger between Ciba-Geigy and Sandoz and their pharmaceutical and agrochemical divisions. It is a pharmaceutical company that is headquartered in Basel, Switzerland, with over 10,000 people working at the Basel Campus from around the world. Novartis reported varying number of employees working in different divisions within the company. There was an decrease from over 65 thousand employees in 2013 to some 59 thousand employees in 2014 working in the pharmaceutical division. Other divisions such as vaccines and diagnostics as well as consumer health also saw an decrease in the number of people employed in this period.
Novartis AG is one of the top pharmaceutical companies in the world with 17.2 billion U.S. dollars in European prescription drug revenues in 2013. In the same year, Novartis AG spent 9.6 billion U.S. dollars on research and development, a large increase from 2004 spending at only 4 billion U.S. dollars. Based on revenue, some of Novartis’ leading drug products include Gleevec/Glivec and Lucentis. Imatinib is marketed as Gleevec in Canada, South Africa, and the United States and as Glivec in Europe, Australia, and Latin America.
